Jonestrading reaffirmed their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. Several other research firms also recently weighed in on FUSN. Royal Bank of Canada reiterated a sector perform rating and issued a $21.00 target price (up previously from $16.00) […]
Leerink Partnrs downgraded shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) from an outperform rating to a market perform rating in a research note released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Fusion Pharmaceuticals’ Q1 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.40) EPS and FY2025 earnings at ($1.42) EPS. Other […]
Fusion Pharmaceuticals (NASDAQ:FUSN) Downgraded to Hold at Brookline Capital Management theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Truist Financial Reaffirms Hold Rating for Fusion Pharmaceuticals (NASDAQ:FUSN) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Free Report) has been given an average rating of “Hold” by the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 […]